Dr. Michael S. Levine, MD

Dr. Levine practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Levine's NPI, 1356415285, was assigned on November 20, 2006. Dr. Levine graduated from David Geffen School of Medicine at UCLA in 1980. Dr. Levine holds California license G46153.

Dr. Levine's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Levine's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. Dr. Levine is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is Cedars-Sinai Medical Group. Dmand AI also links Dr. Levine to 2 more hospitals, 1 physician office and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Levine practices, 6 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Levine's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Levine is board certified in internal medicine by the American Board of Internal Medicine. Dr. Levine is licensed in California.

Dmand AI lists acute sinusitis, asthma, bronchitis, chronic lung disease, chronic obstructive pulmonary disease (COPD), chronic respiratory failure, pleural effusion and pneumonia among the conditions Dr. Levine treats.

CMS data shows 1,842 Medicare services from Dr. Levine across 19 procedure codes in 2024, for 469 Medicare patients. Medicare paid $185,438 for them.

CMS counts 469 Medicare patients who saw Dr. Levine in 2024. The largest group is 65 to 74, with 202 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 15% are also on Medicaid. Their average risk score is 2.22, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Levine's median patient age at 67, with 39% women.

In 2024, Dr. Levine wrote 923 Medicare Part D claims for 190 patients. 65% of them were for generic drugs. CMS names the drug for 564 of them, across 20 drugs with 11 or more claims each, at $152,001 in total drug cost. In 2023, CMS named 620 claims across 22 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Levine for performance year 2024, reported as part of a group. Dr. Levine accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Levine as offering telehealth.

Dmand AI links 116 papers to Dr. Levine, published from 2013 to 2025. 2021 was the busiest year, with 13. The most frequent topics are Gene Expression Regulation, Developmental, Enhancer Elements, Genetic and Transcription Factors. Dr. Levine has published most often in Clin Toxicol (Phila). Dr. Levine's most frequent co-authors are Michael David Levine, MD, Michael A. Levine, MD and Jeffrey Brent, MD.

CMS Open Payments shows 96 general payments to Dr. Levine from 24 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 93% of the total. Daiichi Sankyo Inc. paid the most, $376.

Dmand AI lists 1 award for Dr. Levine.

Dr. Levine graduated from David Geffen School of Medicine at UCLA in 1980.

Dr. Levine is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.